Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference

Rhea-AI Summary

Codex DNA (Nasdaq: DNAY) announced its participation at the SynBioBeta Built with Biology Global Conference from April 12-14, 2022, in Oakland, California. The company will showcase its innovative SOLA enzymatic DNA synthesis technology and BioXp™ products at booth #11. SOLA aims to enhance accuracy, scalability, and cost-effectiveness in synthetic biology workflows. Key presentations will be made by its executives, highlighting advancements in automated workflows for vaccine and therapeutic development.

Positive

• Codex DNA's SOLA technology improves accuracy, scalability, and cost-effectiveness over traditional methods.
• Participation in a prominent conference boosts visibility and credibility in the synthetic biology field.
• The BioXp system accelerates DNA, RNA, and protein synthesis timelines, supporting diverse applications.

Negative

• None.

SOLA approach has the potential to be more accurate, scalable, and cost-effective compared to traditional chemical synthesis and alternative enzymatic techniques for constructing DNA

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) --  Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at SynBioBeta’s Built with Biology Global Conference, which is being held in Oakland, Calif., on April 12-14, 2022. Codex DNA will be showcasing its proprietary short oligo ligation assembly (SOLA) enzymatic DNA synthesis (EDS) technology and its BioXp™ products for end-to-end automated workflows at booth #11.

Codex DNA’s unique SOLA approach addresses many of the challenges facing existing EDS methods related to build length, cost, fidelity, and scalability into synthetic biology workflows. Unlike alternative technologies that employ terminal deoxynucleotidyl transferase (TdT), which incorporates one DNA letter at a time, the streamlined SOLA process generates high-quality synthetic DNA from a universal, pre-manufactured library of short DNA oligos. The short oligos provide the building blocks needed to efficiently assemble complex synthetic genes and mRNA templates using Codex DNA’s industry-standard Gibson Assembly® method on the automated BioXp system. Together, the SOLA technology and BioXp system have the potential to significantly reduce timelines for constructing synthetic DNA, RNA, and proteins for numerous downstream applications including vaccine development, therapeutics development, diagnostics, precision medicine, and DNA data storage.

FEATURED PODIUM PRESENTATIONS:        

• Democratizing Synthetic Biology through SOLA Enzymatic DNA Synthesis and Workflow Automation
  Presenters: Todd Nelson, PhD, CEO, Codex DNA and Dan Gibson, PhD, CTO, Codex DNA
  Date/Time: Tuesday, April 12, 1:30-2:15 pm PT
  Location: Breakout Room 3

• Using Rapid Design-Build-Test Cycles to Transform Legacy Supply Chains via Biomanufacturing
  Presenters: Ben Chiarelli, CEO, Cellibre and Todd Nelson, PhD, CEO, Codex DNA
  Date/Time: Wednesday, April 13, 1:30-2:15 pm PT
  Location: Breakout Room 2

CODEX DNA TECHNOLOGY DEMONSTRATIONS (Booth #11):        

• DNA Libraries on the BioXp System
  Presenter: Kurt Klimpel, PhD, Senior Director, Customer Solutions, Codex DNA
  Date/Time:         
  Tuesday, April 12, 8:30-9:00 am PT
  Wednesday, April 13, 1:00-1:30 pm PT
  Thursday, April 14, 8:30-9:00 am PT
  Location: Codex DNA booth #11

• Automated mRNA Synthesis on the BioXp system
  Presenter: Katie Lyons, Director, Field Applications Science, Codex DNA
  Date/Time:         
  Tuesday, April 12, 1:00-1:30 pm PT
  Wednesday, April 13, 8:30-9:00 am PT
  Thursday, April 14, 1:00-1:30 pm PT
  Location: Codex DNA booth #11

“Codex DNA is proud to present and participate at the preeminent SynBioBeta Built with Biology Global Conference,” said Todd R. Nelson, PhD, CEO of Codex DNA. “We are looking forward to sharing the latest advances from our innovative SOLA EDS technology and automated benchtop solutions that will ultimately enable customers to create high-quality DNA, RNA, and proteins in their own laboratories. Our sustainable, scalable, and cost-effective approach has been designed to significantly accelerate development timelines for the next wave of mRNA-based vaccines and other diagnostics, therapeutics, and personalized medicines.”

About Codex DNA
Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp™ system consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Codex DNA, the Codex DNA logo, Gibson Assembly, and BioXp are trademarks of Codex DNA Inc.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding Codex DNA’s progress made on achieving corporate goals and the future release of products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond Codex DNA’s control, include risks described in Codex DNA’s public filings, specifically the section entitled Risk Factors and elsewhere in its annual Report on Form 10-K, which is anticipated to be filed with the Securities and Exchange Commission on March 23, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Codex DNA disclaims any obligation to update these forward-looking statements.

Media Contact
Richard D. Lepke
Director, Investor Relations
ir@codexdna.com

FAQ

What is the SOLA approach introduced by Codex DNA?

The SOLA approach is a method for enzymatic DNA synthesis that offers higher accuracy, scalability, and cost-effectiveness compared to traditional chemical synthesis methods.

When is the SynBioBeta conference where Codex DNA will present?

The SynBioBeta Built with Biology Global Conference will take place from April 12 to April 14, 2022.

Where can I find Codex DNA during the conference?

Codex DNA will be showcasing its products at booth #11 during the SynBioBeta conference.

What are the applications of Codex DNA's BioXp system?

The BioXp system is used for applications including vaccine development, therapeutics, diagnostics, precision medicine, and DNA data storage.

Who will present at the conference on behalf of Codex DNA?

Presenters from Codex DNA include CEO Todd Nelson and CTO Dan Gibson, among others.